HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…
NASHVILLE, Tenn.--(BUSINESS WIRE)--#centersofexcellence--ObjectiveHealth, a leading integrated specialty research network and technology company, announced today that it has secured a strategic…
NORTHAMPTON, MA / ACCESSWIRE / January 26, 2024 / Inspiration for a greener world can come from unexpected places. For…
ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has…
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA,…
SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX:…
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant dosesAll assessable nectin-4 positive…
WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal…
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024Orion presented yesterday…
NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to…